| Description | Pemetrexed (357166-29-1) is a multi-targeted antifolate with antitumor activity. It potently inhibits folate-dependent enzymes involved in both purine and pyrimidine synthesis including thymidylate synthase (Ki?= 109 nM), dihydrofolate reductase (Ki?= 7 nM), glycinamide ribonucleotide formyltransferase (Ki?= 9.3 μM), and aminoimidazole carboxamide ribonucleotide formyltransferase (Ki?= 3.6 μM).1?A clinically useful anticancer agent.2?Indirectly activates the metabolic kinase AMPK and consequently influences the mTORC1 pathway in human carcinomas.3?Activation of AMPK is associated with pemetrexed resistance.4?Induces G0/G1-phase cell cycle arrest in esophageal squamous cell carcinoma cells.5 |
| Uses | Pemetrexed Disodium Heptahydrate is an chemotherapy drug for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed Disodium Heptahydrate exhibit inhibitory activities toward
s thymidylate synthase as well as other folate dependent enzymes. |
| Uses | Pemetrexed Disodium Heptahydrate is an chemotherapy drug for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed Disodium Heptahydrate exhibit inhibitory activities towards thymidylate synthase as well as other folate dependent enzymes. |
| Uses | These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements. |
| General Description | Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.Pemetrexed is an anionic anticancer drug with a narrow therapeutic index. As a folate anti metabolite, it acts as an inhibitor of thymidylate synthase. It can act effectively against a broad-spectrum of solid tumors such as non-small-cell lung and breast cancers in clinical trials. It is also effective against both dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. |
| Biochem/physiol Actions | Pemetrexed exhibits its activity against several tumors such as colorectal, breast, gastric, pancreatic, and cervical cancer. It acts as a substrate for multidrug resistance protein transporters. |
| References | 1) Shih?et al.?(1997),?LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes; Cancer Res.?57?1116
2) Hanauske?et al. (2001),?Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors; Oncologist?6?363
3) Rothbart?et al. (2010),?Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas; Cancer Res.?70?10299
4) Qin?et al.?(2019),?AMPK activation induced in pemetrexed-treated cells is associated with development of drug resistance independently of target enzyme expression; Mol. Oncol.?13?1419
5) Li?et al.?(2019),?Pemetrexed exerts anticancer effects by inducing G0/G1-phase cell cycle arrest and activating the NOXA/Mcl-1 axis in human esophageal squamous cell carcinoma cells; Oncol. Lett.?17?1851 |
![N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate](/img/357166-29-1.jpg "N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate")
日本语
한국어
Français
Deutsch
España
Türkiye